A Phase 2/3 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Crohn's Disease, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 579 sites in 43 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.
Among the 13 studies testing guselkumab in Crohn Disease, this one has the largest enrollment, is the only one that started in 2018, is the only one in phase 2/3, reaches primary completion later than 1 of the 10 other live ones, and was the 1st registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Austria, Belgium and 14 more countries
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 3
First in 2018; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,409 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 196 across the 13 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 5 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
63 studies in Crohn Disease by Johnson & Johnson: 16 open now, 23 under way, 10 of them phase 3. Of 38 finished, 16 (42%) have results posted.
Among the 63 studies in Crohn Disease by Johnson & Johnson, this one has the largest enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2018, is one of 3 in phase 2/3, reaches primary completion later than 1 of the 22 other live ones, and was the 28th registered.
Johnson & Johnson’s Crohn Disease studies by the year they started, since 1995.
5 of the studies testing guselkumab in Crohn Disease that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT07310095Xian-Janssen Pharmaceutical Ltd.A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) | 2027-09-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies testing guselkumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.
This program consists of 3 separate studies: a 48-week Phase 2 dose-ranging study (GALAXI 1) and two 48-week Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). In Phase 2, safety and efficacy of guselkumab dose regimens will be evaluated to support the selection of induction and maintenance dose regimens for confirmatory evaluation in Phase 3. Participants who complete the 48-week Phase 2 or Phase 3 studies may be eligible to enter the long term extension (LTE). Throughout the 3 studies, efficacy, pharmacokinetic, biomarkers, and safety will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2
Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
Drug: Guselkumab Dose 2 · Drug: Guselkumab Dose 3
Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
Drug: Guselkumab Dose 4 · Drug: Guselkumab Dose 5
Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
Drug: Ustekinumab
Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
Drug: Ustekinumab · Drug: Placebo
Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
Drug: Guselkumab
Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
Drug: Ustekinumab
Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
Drug: Ustekinumab · Drug: Placebo
Guselkumab will be administered by IV infusion.
Guselkumab will be administered by SC injection.
Guselkumab will be administered by IV infusion.
Guselkumab will be administered by IV infusion.
Guselkumab will be by SC injection.
Guselkumab will be administered by IV infusion and SC injection.
Ustekinumab will be administered by IV infusion and SC injection.
Placebo will be administered as IV infusion.
GALAXI 1: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12
The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity. Baseline was defined as the last observation prior to or at the date of the first study intervention.
Time frame: Baseline and Week 12
Global: GALAXI 2: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48
Clinical response was defined as a decrease from baseline (BL) in CDAI score greater than or equal to (\>=) 100 points or CDAI score \<150. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
Time frame: Weeks 48
Global: GALAXI 2: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48
CR: decrease from BL in CDAI score \>=100/\<150. ER: \>=50% improvement from BL in SES-CD score/SES-CD score \<=2. CDAI(8 variables):extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid/soft stools, abdominal pain/cramps, general well-being. Last 3 variables scored over 7 eligible days by participant on diary. Total CDAI score ranged:0-600(in general):higher score=higher disease activities. Decrease in total CDAI score over time=improvement in disease. SES-CD evaluated 4 endoscopic components (presence \& size of ulcer, extent of ulcerated surface, extent of affected surface, presence \& type of narrowing) across 5 ileocolonic segments (ileum; right, left \& transverse colon; rectum) each scored 0(best) to 3(worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. SES-CD score: sum of all component scores(all segments) ranged:0-56, higher scores=more severe disease.
Time frame: Weeks 48
Global: GALAXI 3: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48
Clinical response was defined as a decrease from baseline in CDAI score \>= 100 points or CDAI score \<150. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
Time frame: Weeks 48
Global: GALAXI 3: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48
CR: decrease from BL in CDAI score \>=100/\<150. ER: \>=50% improvement from BL in SES-CD score/SES-CD score \<=2. CDAI(8 variables):extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid/soft stools, abdominal pain/cramps, general well-being. Last 3 variables scored over 7 eligible days by participant on diary. Total CDAI score ranged:0-600(in general):higher score=higher disease activities. Decrease in total CDAI score over time=improvement in disease. SES-CD evaluated 4 endoscopic components (presence \& size of ulcer, extent of ulcerated surface, extent of affected surface, presence \& type of narrowing) across 5 ileocolonic segments (ileum; right, left \& transverse colon; rectum) each scored 0(best) to 3(worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. SES-CD score: sum of all component scores(all segments) ranged:0-56, higher scores=more severe disease.
Time frame: Weeks 48
Regional: GALAXI 2: Percentage of Participants With Clinical Remission at Week 12
Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
Time frame: Week 12
Regional: GALAXI 2: Percentage of Participants With Endoscopic Response at Week 12
Endoscopic response was defined as \>=50% improvement from baseline in SES-CD score or SES-CD score \<=2. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, rectum), each scored 0 (best) to 3 (worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. Total SES-CD score: sum of all component scores across all segments, ranged: 0 to 56, higher scores = more severe disease.
Time frame: Week 12
Regional: GALAXI 3: Percentage of Participants With Clinical Remission at Week 12
Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
Time frame: Week 12
Regional: GALAXI 3: Percentage of Participants With Endoscopic Response at Week 12
Endoscopic response was defined as \>=50% improvement from baseline in SES-CD score or SES-CD score \<=2. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, rectum), each scored 0 (best) to 3 (worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. Total SES-CD score: sum of all component scores across all segments, ranged: 0 to 56, higher scores = more severe disease.
Time frame: Week 12
GALAXI 1: Percentage of Participants With Clinical Remission at Week 12
Time frame: At Week 12
GALAXI 1: Percentage of Participants With Clinical Response at Week 12
Time frame: At Week 12
GALAXI 1: Percentage of Participants With Patient-Reported Outcome (PRO) 2 Remission at Week 12
Time frame: At Week 12
GALAXI 1: Percentage of Participants With Clinical-Biomarker Response at Week 12
Time frame: At Week 12
GALAXI 1: Percentage of Participants With Endoscopic Response at Week 12
Time frame: At Week 12
Global: GALAXI 2 and 3: Percentage of Participants With Clinical Response at Week 4
Time frame: At Week 4
Global: GALAXI 2 and 3: Percentage of Participants With Clinical Remission at Week 12
Time frame: At Week 12
Global: GALAXI 2 and 3: Percentage of Participants With Endoscopic Response at Week 12
Time frame: At Week 12
Global: GALAXI 2 and 3: Percentage of Participants With Fatigue Response at Week 12
Time frame: At Week 12
Global: GALAXI 2 and 3: Percentage of Participants With Both Clinical Remission and Endoscopic Response at Week 12
Time frame: At Week 12
Global: GALAXI 2 and 3: Percentage of Participants With Endoscopic Remission at Week 12
Time frame: At Week 12
Global: GALAXI 2 and 3: Percentage of Participants With Both Clinical Response at Week 12 and Corticosteroid-Free Clinical Remission at Week 48
Time frame: At Week 48
Global: GALAXI 2 and 3: Percentage of Participants With Both Clinical Response at Week 12 and Endoscopic Remission at Week 48
Time frame: At Week 48
Global: GALAXI 2 and 3: Percentage of Participants With Clinical Remission at Week 48
Time frame: At Week 48
Global: GALAXI 2 and 3: Percentage of Participants With Endoscopic Response at Week 48
Time frame: At Week 48
Global: GALAXI 2 and 3: Percentage of Participants With Both Clinical Remission and Endoscopic Response at Week 48
Time frame: At Week 48
Global: GALAXI 2 and 3: Percentage of Participants With Endoscopic Remission at Week 48
Time frame: At Week 48
Global: GALAXI 2 and 3: Percentage of Participants With Deep Remission at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With PRO-2 Remission at Week 12
Time frame: At Week 12
Regional: GALAXI 2 and 3: Percentage of Participants With Fatigue Response at Week 12
Time frame: At Week 12
Regional: GALAXI 2 and 3: Percentage of Participants With Endoscopic Remission at Week 12
Time frame: At Week 12
Regional: GALAXI 2 and 3: Percentage of Participants With Corticosteroid-free Clinical Remission at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With Endoscopic Response at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With Endoscopic Remission at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With Clinical Remission at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With Durable Clinical Remission at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With PRO-2 Remission at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With Both Clinical Remission at Week 48 and Endoscopic Response at Week 48
Time frame: At Week 48
Regional: GALAXI 2 and 3: Percentage of Participants With Corticosteroid-free Remission at Week 48
Time frame: At Week 48
This study consisted of 3 separate studies: Phase 2 dose-ranging study (GALAXI 1) and 2 identical Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). Participants with moderately to severely active Crohn's disease were enrolled in these studies.
| Milestone | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 73 | 73 | 73 | 71 | 70 | 148 | 149 | 150 | 77 | 151 | 148 | 150 | 76 |
| Participants who did not achieve cr at week 12 and crossed over to ustekinumab | 0 | 0 | 0 | 0 | 43 | 0 | 0 | 0 | 49 | 0 | 0 | 0 | 51 |
| Completed | 58 | 64 | 64 | 66 | 62 | 145 | 141 | 140 | 71 | 138 | 131 | 137 | 69 |
| Not completed | 15 | 9 | 9 | 5 | 8 | 3 | 8 | 10 | 6 | 13 | 17 | 13 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 14 | 7 | 8 | 4 | 6 | 3 | 6 | 9 | 6 | 11 | 14 | 12 | 7 |
| Withdrew: Other | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity. Baseline was defined as the last observation prior to or at the date of the first study intervention.
| Units on a scale | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w |
|---|---|---|---|---|
| GALAXI 1: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12 | -143.7 ± 96.58 | -139.2 ± 100.71 | -159.8 ± 110.52 | -34.4 ± 104.85 |
Clinical response was defined as a decrease from baseline (BL) in CDAI score greater than or equal to (\>=) 100 points or CDAI score \<150. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
| Percentage of participants | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w |
|---|---|---|---|
| Global: GALAXI 2: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48 | 54.8 | 49.0 | 11.8 |
CR: decrease from BL in CDAI score \>=100/\<150. ER: \>=50% improvement from BL in SES-CD score/SES-CD score \<=2. CDAI(8 variables):extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid/soft stools, abdominal pain/cramps, general well-being. Last 3 variables scored over 7 eligible days by participant on diary. Total CDAI score ranged:0-600(in general):higher score=higher disease activities. Decrease in total CDAI score over time=improvement in disease. SES-CD evaluated 4 endoscopic components (presence \& size of ulcer, extent of ulcerated surface, extent of affected surface, presence \& type of narrowing) across 5 ileocolonic segments (ileum; right, left \& transverse colon; rectum) each scored 0(best) to 3(worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. SES-CD score: sum of all component scores(all segments) ranged:0-56, higher scores=more severe disease.
| Percentage of participants | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w |
|---|---|---|---|
| Global: GALAXI 2: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48 | 38.4 | 39.2 | 5.3 |
Clinical response was defined as a decrease from baseline in CDAI score \>= 100 points or CDAI score \<150. Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
| Percentage of participants | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w |
|---|---|---|---|
| Global: GALAXI 3: Percentage of Participants With Both Clinical Response at Week 12 and Clinical Remission at Week 48 | 48.0 | 46.9 | 12.5 |
CR: decrease from BL in CDAI score \>=100/\<150. ER: \>=50% improvement from BL in SES-CD score/SES-CD score \<=2. CDAI(8 variables):extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid/soft stools, abdominal pain/cramps, general well-being. Last 3 variables scored over 7 eligible days by participant on diary. Total CDAI score ranged:0-600(in general):higher score=higher disease activities. Decrease in total CDAI score over time=improvement in disease. SES-CD evaluated 4 endoscopic components (presence \& size of ulcer, extent of ulcerated surface, extent of affected surface, presence \& type of narrowing) across 5 ileocolonic segments (ileum; right, left \& transverse colon; rectum) each scored 0(best) to 3(worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. SES-CD score: sum of all component scores(all segments) ranged:0-56, higher scores=more severe disease.
| Percentage of participants | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w |
|---|---|---|---|
| Global: GALAXI 3: Percentage of Participants With Both Clinical Response (CR) at Week 12 and Endoscopic Response (ER) at Week 48 | 36.0 | 33.6 | 5.6 |
Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
| Percentage of participants | GALAXI 2 Placebo (From Group 4) | GALAXI 2 Combined Guselkumab 200 mg IV (Group 1+ Group 2) |
|---|---|---|
| Regional: GALAXI 2: Percentage of Participants With Clinical Remission at Week 12 | 22.4 | 47.1 |
Endoscopic response was defined as \>=50% improvement from baseline in SES-CD score or SES-CD score \<=2. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, rectum), each scored 0 (best) to 3 (worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. Total SES-CD score: sum of all component scores across all segments, ranged: 0 to 56, higher scores = more severe disease.
| Percentage of participants | GALAXI 2 Placebo (From Group 4) | GALAXI 2 Combined Guselkumab 200 mg IV (Group 1+ Group 2) |
|---|---|---|
| Regional: GALAXI 2: Percentage of Participants With Endoscopic Response at Week 12 | 10.5 | 37.7 |
Clinical remission was defined as a CDAI score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 eligible days by the participant on a diary card. The total CDAI score ranged from 0 to 600 in general: higher score indicated higher disease activities. A decrease in total CDAI score over time indicates improvement in disease activity.
| Percentage of participants | GALAXI 3 Placebo (From Group 4) | GALAXI 3 Combined Guselkumab 200 mg IV (Group 1+ Group 2) |
|---|---|---|
| Regional: GALAXI 3: Percentage of Participants With Clinical Remission at Week 12 | 15.3 | 47.1 |
Endoscopic response was defined as \>=50% improvement from baseline in SES-CD score or SES-CD score \<=2. SES-CD evaluated 4 endoscopic components (presence and size of ulcer, extent of ulcerated surface, extent of affected surface, presence and type of narrowing) across 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, rectum), each scored 0 (best) to 3 (worst) except narrowing component for which maximum total score (that is, stricturing) was 11 points. Total SES-CD score: sum of all component scores across all segments, ranged: 0 to 56, higher scores = more severe disease.
| Percentage of participants | GALAXI 3 Placebo (From Group 4) | GALAXI 3 Combined Guselkumab 200 mg IV (Group 1+ Group 2) |
|---|---|---|
| Regional: GALAXI 3: Percentage of Participants With Endoscopic Response at Week 12 | 13.9 | 36.2 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From Week 0 up to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | 0/73 (0%) | 5/73 (6.8%) | 33/73 (45.2%) |
| GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | 0/73 (0%) | 5/73 (6.8%) | 34/73 (46.6%) |
| GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | 0/73 (0%) | 6/73 (8.2%) | 34/73 (46.6%) |
| GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | 0/71 (0%) | 9/71 (12.7%) | 44/71 (62%) |
| GALAXI 1 (Group 5) Placebo q4w | 0/70 (0%) | 6/70 (8.6%) | 27/70 (38.6%) |
| GALAXI 1 (Group 5) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | 0/43 (0%) | 0/43 (0%) | 16/43 (37.2%) |
| GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | 0/148 (0%) | 6/148 (4.1%) | 80/148 (54.1%) |
| GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | 0/149 (0%) | 19/148 (12.8%) | 66/148 (44.6%) |
| GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | 0/150 (0%) | 18/150 (12%) | 78/150 (52%) |
| GALAXI 2 (Group 4) Placebo q4w | 0/77 (0%) | 6/77 (7.8%) | 21/77 (27.3%) |
| GALAXI 2 (Group 4) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | 0/49 (0%) | 3/49 (6.1%) | 15/49 (30.6%) |
| GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | 0/151 (0%) | 15/151 (9.9%) | 80/151 (53%) |
| GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | 0/148 (0%) | 13/148 (8.8%) | 69/148 (46.6%) |
| GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | 0/150 (0%) | 17/150 (11.3%) | 73/150 (48.7%) |
| GALAXI 3 (Group 4) Placebo q4w | 0/76 (0%) | 10/76 (13.2%) | 30/76 (39.5%) |
| GALAXI 3 (Group 4) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | 0/51 (0%) | 6/51 (11.8%) | 19/51 (37.3%) |
| Event | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w | GALAXI 1 (Group 5) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w | GALAXI 2 (Group 4) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w | GALAXI 3 (Group 4) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crohn's DiseaseGastrointestinal disorders | 0/73 | 0/73 | 0/73 | 3/71 | 1/70 | 0/43 | 0/148 | 5/148 | 3/150 | 3/77 | 1/49 | 3/151 | 4/148 | 1/150 | 6/76 | 2/51 |
| Anal AbscessInfections and infestations | 0/73 | 0/73 | 2/73 | 0/71 | 0/70 | 0/43 | 0/148 | 1/148 | 0/150 | 0/77 | 0/49 | 0/151 | 0/148 | 1/150 | 0/76 | 0/51 |
| Anal FistulaGastrointestinal disorders | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 0/148 | 1/148 | 0/150 | 0/77 | 0/49 | 1/151 | 0/148 | 0/150 | 2/76 | 0/51 |
| BronchitisInfections and infestations | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 0/148 | 0/148 | 0/150 | 0/77 | 1/49 | 0/151 | 0/148 | 0/150 | 0/76 | 0/51 |
| Covid-19Infections and infestations | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 0/148 | 0/148 | 0/150 | 0/77 | 1/49 | 0/151 | 0/148 | 0/150 | 0/76 | 0/51 |
| Abdominal PainGastrointestinal disorders | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 0/148 | 1/148 | 0/150 | 1/77 | 0/49 | 0/151 | 0/148 | 3/150 | 1/76 | 0/51 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/73 | 0/73 | 1/73 | 1/71 | 0/70 | 0/43 | 0/148 | 0/148 | 0/150 | 0/77 | 0/49 | 3/151 | 1/148 | 1/150 | 0/76 | 0/51 |
| Intestinal ObstructionGastrointestinal disorders | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 1/148 | 1/148 | 0/150 | 0/77 | 0/49 | 2/151 | 1/148 | 2/150 | 1/76 | 1/51 |
| Abdominal AbscessInfections and infestations | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 0/148 | 0/148 | 2/150 | 0/77 | 0/49 | 0/151 | 0/148 | 0/150 | 0/76 | 1/51 |
| Abscess LimbInfections and infestations | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 0/148 | 0/148 | 0/150 | 0/77 | 0/49 | 0/151 | 0/148 | 0/150 | 0/76 | 1/51 |
| Event | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w | GALAXI 1 (Group 5) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w | GALAXI 2 (Group 4) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w | GALAXI 3 (Group 4) Placebo Followed by Ustekinumab 6 mg/kg IV Then 90 mg SC q8w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covid-19Infections and infestations | 0/73 | 0/73 | 0/73 | 0/71 | 0/70 | 0/43 | 22/148 | 18/148 | 24/150 | 2/77 | 7/49 | 31/151 | 27/148 | 16/150 | 8/76 | 5/51 |
| Crohn's DiseaseGastrointestinal disorders | 4/73 | 5/73 | 6/73 | 11/71 | 4/70 | 5/43 | 12/148 | 8/148 | 12/150 | 8/77 | 2/49 | 11/151 | 10/148 | 11/150 | 8/76 | 4/51 |
| HeadacheNervous system disorders | 7/73 | 10/73 | 5/73 | 6/71 | 1/70 | 4/43 | 16/148 | 6/148 | 13/150 | 3/77 | 1/49 | 8/151 | 9/148 | 6/150 | 4/76 | 0/51 |
| NasopharyngitisInfections and infestations | 8/73 | 9/73 | 8/73 | 8/71 | 3/70 | 4/43 | 10/148 | 7/148 | 12/150 | 2/77 | 1/49 | 11/151 | 5/148 | 7/150 | 3/76 | 2/51 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/73 | 4/73 | 8/73 | 5/71 | 4/70 | 3/43 | 14/148 | 14/148 | 12/150 | 4/77 | 3/49 | 11/151 | 9/148 | 8/150 | 1/76 | 2/51 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/73 | 6/73 | 2/73 | 7/71 | 6/70 | 2/43 | 12/148 | 15/148 | 10/150 | 3/77 | 2/49 | 13/151 | 14/148 | 13/150 | 3/76 | 5/51 |
| AnaemiaBlood and lymphatic system disorders | 3/73 | 6/73 | 1/73 | 7/71 | 4/70 | 1/43 | 10/148 | 8/148 | 11/150 | 3/77 | 1/49 | 5/151 | 7/148 | 5/150 | 5/76 | 3/51 |
| PyrexiaGeneral disorders | 4/73 | 3/73 | 6/73 | 5/71 | 2/70 | 1/43 | 8/148 | 10/148 | 14/150 | 5/77 | 1/49 | 8/151 | 9/148 | 12/150 | 3/76 | 3/51 |
| Abdominal PainGastrointestinal disorders | 2/73 | 2/73 | 1/73 | 5/71 | 3/70 | 0/43 | 9/148 | 11/148 | 13/150 | 3/77 | 1/49 | 5/151 | 8/148 | 12/150 | 4/76 | 0/51 |
| NauseaGastrointestinal disorders | 2/73 | 2/73 | 3/73 | 4/71 | 2/70 | 0/43 | 5/148 | 5/148 | 6/150 | 1/77 | 0/49 | 4/151 | 4/148 | 4/150 | 6/76 | 0/51 |
Baseline characteristics data were presented for all randomized participants who received at least 1 dose of study intervention.
| Age, Categorical(Participants) | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 68 | 66 | 69 | 69 | 68 | 142 | 144 | 143 | 76 | 143 | 146 | 143 | 75 | 1352 |
| >=65 years | 5 | 7 | 4 | 2 | 2 | 6 | 4 | 7 | 1 | 8 | 2 | 7 | 1 | 56 |
| Age, Continuous(Years) | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 40.2 ± 14.28 | 39.3 ± 15.51 | 41.5 ± 14.41 | 36.3 ± 12.08 | 39 ± 12.79 | 36.2 ± 13.03 | 37.3 ± 12.86 | 37 ± 12.76 | 34.1 ± 11.81 | 37.6 ± 13.4 | 34.8 ± 11.48 | 37.9 ± 13.61 | 35.8 ± 12.48 | 37.2 ± 13.14 |
| Sex: Female, Male(Participants) | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 35 | 29 | 27 | 26 | 26 | 59 | 76 | 62 | 35 | 59 | 60 | 66 | 26 | 586 |
| Male | 38 | 44 | 46 | 45 | 44 | 89 | 72 | 88 | 42 | 92 | 88 | 84 | 50 | 822 |
| Ethnicity (NIH/OMB)(Participants) | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 4 | 0 | 4 | 8 | 5 | 7 | 2 | 5 | 7 | 11 | 4 | 65 |
| Not Hispanic or Latino | 69 | 64 | 66 | 69 | 64 | 136 | 139 | 137 | 71 | 142 | 136 | 131 | 71 | 1295 |
| Unknown or Not Reported | 1 | 4 | 3 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 5 | 8 | 1 | 48 |
| Race (NIH/OMB)(Participants) | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian | 6 | 10 | 9 | 8 | 5 | 28 | 34 | 32 | 17 | 28 | 38 | 23 | 19 | 257 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 2 | 11 |
| Black or African American | 2 | 2 | 0 | 1 | 3 | 1 | 3 | 3 | 0 | 1 | 0 | 4 | 3 | 23 |
| White | 61 | 59 | 58 | 61 | 58 | 117 | 108 | 111 | 56 | 118 | 107 | 116 | 50 | 1080 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 | 0 | 4 | 2 | 3 | 4 | 2 | 4 | 2 | 6 | 2 | 35 |
| Region of Enrollment(Participants) | GALAXI 1 (Group 1) Guselkumab 1200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 2) Guselkumab 600 mg IV q4w Followed by 200 mg SC q4w | GALAXI 1 (Group 3) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 1 (Group 4) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 1 (Group 5) Placebo q4w Followed by Placebo q4w or Ustekinumab 6mg/kg IV Then 90mg SC q8w | GALAXI 2 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 2 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 2 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 2 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | GALAXI 3 (Group 1) Guselkumab 200 mg IV q4w Followed by 200 mg SC q4w | GALAXI 3 (Group 2) Guselkumab 200 mg IV q4w Followed by 100 mg SC q8w | GALAXI 3 (Group 3) Ustekinumab 6 mg/kg IV Followed by 90 mg SC q8w | GALAXI 3 (Group 4) Placebo q4w Followed by Placebo q4w or Ustekinumab 6 mg/kg IV Then 90 mg SC q8w | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 1 | 0 | 0 | 0 | 0 | 5 | 2 | 6 | 1 | 2 | 1 | 3 | 1 | 22 |
| Austria | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Belarus | 2 | 1 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 10 |
| Belgium | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 5 |
| Bosnia and Herzegovina | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 3 | 1 | 0 | 2 | 2 | 0 | 14 |
| Brazil | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 9 | 2 | 8 | 6 | 12 | 3 | 53 |
| Canada | 0 | 0 | 2 | 0 | 0 | 1 | 6 | 4 | 1 | 2 | 4 | 5 | 2 | 27 |
| China | 0 | 0 | 0 | 0 | 0 | 18 | 19 | 10 | 12 | 15 | 22 | 12 | 12 | 120 |
| Colombia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Croatia | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 4 |
| Czech Republic | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 3 | 1 | 4 | 1 | 1 | 16 |
| France | 2 | 2 | 6 | 1 | 2 | 4 | 2 | 4 | 2 | 1 | 1 | 2 | 1 | 30 |
| Georgia | 1 | 3 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 10 |
| Germany | 3 | 4 | 0 | 2 | 2 | 2 | 4 | 2 | 0 | 4 | 2 | 1 | 1 | 27 |
| Greece | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hungary | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 5 | 0 | 4 | 1 | 4 | 1 | 20 |
| India | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 2 | 2 | 0 | 10 |
| Israel | 2 | 2 | 2 | 2 | 0 | 4 | 1 | 0 | 2 | 0 | 9 | 0 | 2 | 26 |
| Italy | 2 | 2 | 2 | 0 | 1 | 1 | 0 | 1 | 1 | 3 | 1 | 0 | 1 | 15 |
| Japan | 3 | 5 | 6 | 4 | 2 | 4 | 7 | 13 | 1 | 9 | 6 | 4 | 4 | 68 |
| Jordan | 1 | 1 | 0 | 2 | 1 | 4 | 3 | 4 | 4 | 9 | 3 | 9 | 1 | 42 |
| Latvia | 3 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 10 |
| Lebanon | 0 | 0 | 0 | 1 | 0 | 1 | 4 | 1 | 1 | 2 | 3 | 4 | 2 | 19 |
| Lithuania | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Malaysia | 1 | 2 | 0 | 1 | 0 | 3 | 1 | 2 | 1 | 0 | 2 | 1 | 1 | 15 |
| Netherlands | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 4 | 1 | 2 | 0 | 12 |
| New Zealand | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 3 | 1 | 2 | 1 | 0 | 0 | 12 |
| Poland | 11 | 18 | 15 | 21 | 25 | 33 | 24 | 33 | 10 | 26 | 32 | 28 | 16 | 292 |
| Portugal | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 4 |
| Macedonia | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Russian Federation | 6 | 3 | 8 | 4 | 3 | 14 | 14 | 14 | 10 | 13 | 9 | 9 | 8 | 115 |
| Saudi Arabia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Slovakia | 1 | 1 | 0 | 2 | 2 | 1 | 3 | 1 | 0 | 3 | 2 | 1 | 0 | 17 |
| Korea, South | 1 | 2 | 1 | 3 | 2 | 2 | 5 | 4 | 2 | 2 | 3 | 3 | 2 | 32 |
| Spain | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 3 | 0 | 12 |
| Serbia | 2 | 3 | 3 | 6 | 2 | 8 | 9 | 7 | 3 | 5 | 2 | 8 | 6 | 64 |
| Taiwan | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Tunisia | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 1 | 1 | 5 | 2 | 1 | 1 | 19 |
| Turkey | 1 | 1 | 0 | 2 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 10 |
| Ukraine | 9 | 7 | 7 | 7 | 6 | 11 | 12 | 7 | 8 | 11 | 10 | 7 | 4 | 106 |
| United Kingdom | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 5 |
| United States | 14 | 10 | 13 | 6 | 14 | 7 | 6 | 8 | 2 | 10 | 9 | 15 | 5 | 119 |
Showing the first 100 of 579 sites across 43 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Oct 2023, 66 months.
Results were first posted in May 2025, 1 year 6 months after primary completion. A results delay was requested in Oct 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Guselkumab · Ustekinumab
Janssen Research & Development, LLC →